Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Aug:22:101459.
doi: 10.1016/j.tranon.2022.101459. Epub 2022 May 23.

Resistance against anti-CD19 and anti-BCMA CAR T cells: Recent advances and coping strategies

Pinar Ataca Atilla  1 , Erden Atilla  2
Affiliations
Review

Resistance against anti-CD19 and anti-BCMA CAR T cells: Recent advances and coping strategies

Pinar Ataca Atilla et al. Transl Oncol. 2022 Aug.

Abstract

Chimeric antigen receptor T (CAR T) cell therapy is a new treatment paradigm that has revolutionized the treatment of CD19-positive B cell malignancies and BCMA-positive plasma cell malignancies. The response rates are highly impressive in comparison to historical cohorts, but the responses are not durable. The most recent results from pivotal trials show that current CAR T cell products fail to demonstrate optimal long-term disease control. Resistance to CAR T cells is related to CAR structure, T cell factors, tumor factors and the immunosuppressive microenvironment. Novel strategies are needed following failure with CAR T cell treatment. In this review, we discuss the resistance mechanisms to CAR T cell treatment according to disease and the emerging strategies to overcome resistance.

Keywords: BCMA; CD19; Chimeric antigen receptor T cells; Immunotherapy; Resistance.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Figures

Image, graphical abstract
Graphical abstract
Fig 1
Fig. 1
Resistance mechanisms of CD19 CAR T cells. A. Murine scFV is an immunogeneic epitope B. Different spacer and transmembrane domains effect CAR T cell efficacy. Costimulation domains regulate persistence and exhaustion C. Tonic signaling can limit the power of CAR T cells. D. T cell characteristics may effect the clinical response (T cell phenotype, T cell aging, T cell exhaustion). E. In antigen negative relapses loss of antigen, splicing variations, lineage swiching, trogocytosis are important mechanisms. F. Tumors may be lack of pro-apoptotic molecules.
See this image and copyright information in PMC

References

    1. Rosenbaum L. Tragedy, perseverance, and chance - the story of CAR- T therapy. N. Engl. J. Med. 2017;377:1313–1315. - PubMed
    1. Caruso H.G., et al. Tuning sensitivity of CAR to EGFR density limits recognition of normal tissue while maintaining potent antitumor activity. Cancer Res. 2015;75:3505–3518. - PMC - PubMed
    1. Watanabe K. Excessively high-affinity single- chain fragment variable region in a chimeric antigen receptor can counteract T-cell proliferation. Blood. 2014;124:4799. –4799.
    1. Jensen M.C., et al. Designing chimeric antigen receptors to effectively and safely target tumors. Curr. Opin. Immunol. 2015;33:9–15. - PMC - PubMed
    1. Bridgeman J.S., et al. The optimal antigen response of chimeric antigen receptors harboring the CD3ζ transmembrane domain is dependent upon incorporation of the receptor into the endogenous TCR/CD3 complex. J. Immunol. 2010;184:6938–6949. - PubMed